



# BerGenBio to present at DNB's Nordic Healthcare Conference

**BERGEN, Norway, December 8, 2022** – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 13th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 15, 2022, at 11:45am CET.

The presentation will be made available on the Company website in the presentations section on the day of the event:

[www.bergenbio.com/investors/presentations/](http://www.bergenbio.com/investors/presentations/)

-End-

## Contacts

Martin Olin CEO, BerGenBio ASA

[ir@bergenbio.com](mailto:ir@bergenbio.com)

Rune Skeie, CFO, BerGenBio ASA

[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)

## Investor Relations / Media Relations

Graham Morrell

[graham.morrell@bergenbio.com](mailto:graham.morrell@bergenbio.com)

## About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit [www.bergenbio.com](http://www.bergenbio.com)

## Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

**This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.**